Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes diagnostic and therapeutic molecular nuclear medicine, or MNM, products.

AAA is at the forefront of developing predictive, preventive and personalized tools and procedures that have the potential to radically transform healthcare. Our path to accomplishing this goal is by merging therapeuti... more >

Materials for June 20, 2018 Annual Meeting
  • 2018 AGM Agenda and Resolution ENG | FR
Latest Newsmore >
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
SAINT-GENIS-POUILLY, France, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a Novartis company and leader in nuclear medicine theragnostics, today announced that it has entered into an exclusive worldwide license agreement with Cancer Targeted Technology, LLC (CTT) to develop and market an investigational new drug product, F-18-labeled CTT1057. CTT1057 is a ligand of Prostate-Specific Membrane Antigen (PSMA) for Positron Emission To... 
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer
SAINT-GENIS-POUILLY, France, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a Novartis company and a leader in nuclear medicine theragnostics, today announced that a subsidiary of Novartis AG (NYSE:NVS) (“Novartis”), Novartis Groupe France S.A. (“Purchaser”), has completed the subsequent offering period of the tender offer to purchase all of the outstanding ordinary shares (“Ordinary Shares”), including Ordinary Shares represent... 
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients Lutathera (lutetium Lu 177 dotatate) vial picture ... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources